Get started
Author

Claes Ginman

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
2019 · Anders Widmark, Adalsteinn Gunnlaugsson, et al. · The Lancet · 916
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
2013 · Pirkko-Liisa Kellokumpu-Lehtinen, Ulrika Harmenberg, et al. · The Lancet Oncology · 214
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
2021 · Per Fransson, Per Nilsson, et al. · The Lancet Oncology · 165
Patient-controlled dose regimen of methadone for chronic cancer pain.
1981 · J Sawe, J Hansen, et al. · BMJ · 109
PDF
Adipose Tissue Concentrations of Persistent Organic Pollutants and the Risk of Prostate Cancer
2006 · Lennart Hardell, Swen-Olof Andersson, et al. · Journal of Occupational and Environmental Medicine · 95
Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study
2007 · Sophie D. Fosså, Anne-Birgitte Jacobsen, et al. · European Urology · 60
Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study
2005 · Sten Nilsson, Peter Strang, et al. · Journal of Pain and Symptom Management · 41
PDF
Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer: Early Toxicity Results from the Scandinavian Randomized Phase III Trial “HYPO-RT-PC”
2016 · A. Widmark, A. Gunnlaugsson, et al. · International Journal of Radiation Oncology*Biology*Physics · 37
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial
2019 · Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, et al. · European Urology · 32
Preoperative Irradiation of Primarily Non-Resectable Adenocarcinoma of the Rectum and Rectosigmoid
1985 · L. Påhlman, B. Glimelius, et al. · Acta Radiologica Oncology · 32
PDF
Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial
2012 · P-L Kellokumpu-Lehtinen, M Hjälm-Eriksson, et al. · Prostate Cancer and Prostatic Diseases · 28
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.
2012 · Petteri Hervonen, Heikki Joensuu, et al. · PubMed · 24
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
2026 · Per Nilsson, Adalsteinn Gunnlaugsson, et al. · The Lancet Oncology · 22
OC-0599: Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial
2018 · A. Widmark, A. Gunnlaugsson, et al. · Radiotherapy and Oncology · 22
PDF
Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma
1997 · Karl-Mikael Kälkner, Claes Ginman, et al. · Nuclear Medicine and Biology · 22
Sequential methotrexate-5-FU-leucovorin (MFL) in advanced colorectal cancer
1986 · Bengt Glimelius, Claes Ginman, et al. · European Journal of Cancer and Clinical Oncology · 22
Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial
2019 · Marina Forslund, Anna Ottenblad, et al. · Supportive Care in Cancer · 19
PDF
Clinical Evaluation of Oral Methadone in Treatment of Cancer Pain
1982 · J. Hansen, C. Ginman, et al. · Acta Anaesthesiologica Scandinavica · 17
A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.
2018 · Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, et al. · Journal of Clinical Oncology · 12
11C-methionine Positrone Emission Tomography in the management of prostatic Carcinoma.
1995 · S. Nilsson, M Kalkner, et al. · 10
4981 Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321)
2025 · Per Nilsson, Adalsteinn Gunnlaugsson, et al. · Radiotherapy and Oncology · 4
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial
2022 · Miikka Lehtonen, Jorma Sormunen, et al. · Acta Oncologica · 4
Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis.
2014 · Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, Ulrika Harmenberg, et al. · Journal of Clinical Oncology · 2
High toxicity in patients receiving adjuvant docetaxel plus hormone treatment after radical radiotherapy for high-risk prostate cancer: A preplanned safety report of SPCG 13 trial.
2011 · P. Kellokumpu-Lehtinen, M. Hjelm-Eriksson, et al. · Journal of Clinical Oncology · 2
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study
2021 · MIIKKA LEHTONEN, JORMA SORMUNEN, et al. · Anticancer Research · 1
PDF
Works count: 30
Citation count: 1,913
H-index: 17
I10-index: 20
Year
Topic
Type